Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Часто задаваемые вопросы
В каком секторе работает Alterity Therapeutics Limited (ATHE)?
Alterity Therapeutics Limited относится к сектору Здравоохранение.
Какова текущая цена акций Alterity Therapeutics Limited (ATHE)?
По последним данным, цена акций Alterity Therapeutics Limited составляет 4,56 $, предыдущее закрытие — 4,57 $. За последнюю торговую сессию акции Alterity Therapeutics Limited снизились на -0,01 $, что соответствует падению на -0,15%.
Выплачивает ли Alterity Therapeutics Limited (ATHE) дивиденды?
Нет, Alterity Therapeutics Limited не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Alterity Therapeutics Limited (ATHE)?
У компании Alterity Therapeutics Limited бета -0.035, что указывает на более низкую волатильность по сравнению с рынком в целом.
